ISSN: 2161-0460

Journal de la maladie d'Alzheimer et du parkinsonisme

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • Clés académiques
  • JournalTOC
  • Infrastructure nationale du savoir de Chine (CNKI)
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

Individual PKR Activation in Peripheral Blood Mononuclear Cells Correlates with Cognitive Decline in Alzheimer’s Disease

Julian A, Page G, Rioux Bilan A, Dugast E, Morel M, Ragot S and Paccalin M

Background: Among the pathogenic processes in Alzheimer’s Disease (AD), systemic inflammation, autophagy and metabolic alterations have been described. The double-stranded RNA-dependent protein kinase (PKR) is an ubiquitous cellular kinase involved in these several pathogenic processes, and previous studies reported its involvement in AD. PKR can be activated by phosphorylation (PT451-PKR) and cleaved in catalytic form (PKR-KD). We have previously described a correlation between PKR activation in peripheral blood mononuclear cells (PBMCs) and cognitive status in advanced AD. However, the link between PKR’s activation in PBMCs and cognitive decline in AD remains unknown.
Methods: Thirty-one patients with AD were included. Acute and chronic inflammations were considered as exclusion criteria. Cognitive status was assessed with Mini Mental State Examination (MMSE) and AD assessment scale (ADAScog) at baseline, 6, 12 and 24 months of follow-up. PKR expression and its activation were measured using western blot at baseline, 12 and 24 months.
Results: At baseline, MMSE mean score was 20.5 ± 2.6; Except for total PKR expression between baseline and M12, no longitudinal significant variation of PKR activation was found. Higher PKR-KD activation was correlated with faster cognitive decline at an individual level at M6 (r=0.33, p=0.0453), M12 (r=0.48, p=0.0033) and M24 (r=0.36, p=0.0407). Other PKR forms were correlated with cognitive decline at M12.
Conclusions: Our results suggest that PKR activation in PBMCSs can predict cognitive decline in AD at an early stage at an individual level.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.